Human Reproductive Technologies - Global Strategic Business Report

Description: This report analyzes the worldwide markets for Human Reproductive Technologies in US$ Million by the following Product Segments: Contraceptive Technologies, and Infertility Technologies. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa, and Latin America.

Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

The report profiles 102 companies including many key and niche players such as -

Actavis, Inc.
Ansell Limited
Agile Therapeutics, Inc.
Bayer HealthCare
Church & Dwight Co., Inc.

Contents:

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW
A Prelude to Human Reproductive Technologies
In-Vitro Fertilization (IVF) - The Leading Infertility Treatment
Table 1: IVF Practice by Region (2014): Percentage Breakdown of No. of IVF Cycles Performed per year for Global Regions (includes corresponding Graph/Chart)
Contraceptives

2. MARKET SEGMENTATION
Infertility - Overview
Table 2: Average Age of First-time Mothers by Year and Country (1970 and 2006) (includes corresponding Graph/Chart)
Causes
Table 3: Infertility Causes in the US by Gender: Percentage Share of Female, Male, Female-Male Combined, and Unknown Factors (includes corresponding Graph/Chart)
Treatment
Fertility Enhancement Drugs
Commonly Used Fertility Drugs
Major Brands of Fertility Enhancement/ Ovulation-Induction Drugs
Gonadotropin Therapy
Major Gonadotropin Drugs Used Worldwide
Assisted Reproductive Technology (ART)
Table 4: ART Therapy by Gamete Source (2014): Percentage Share Breakdown of Number of Procedures using fresh non-donor eggs, fresh donor eggs, frozen non-donor eggs, frozen donor eggs, and Embryo/Egg Banking (includes corresponding Graph/Chart)
Table 5: Cumulative Success Rates of IVF by Number of Cycles: Percentage of Success with one, two & three cycles (includes corresponding Graph/Chart)
Table 6: IVF Success Rates by Age Group (2014): No. of IVF Cycles Performed, and Percentage of Successful
Pregnancies and Live Births for Women <35, 35-37, 38-40, 41-42, 43-44, and >44 Yrs (includes corresponding Graph/Chart)

Table 7: Average Costs of Different ART Methods

Costs

Table 8: Average Expenditure Involved for Different Types of Adoption in the US

Key Growth Drivers/Trends of the Infertility Market

Increasing Maternal Age Leading to Infertility Issues

Table 9: Mounting Infertility Rates by Age: Rate of Infertility for Women in 15-29, 30-34, 35-39, and 40-44 Age groups (includes corresponding Graph/Chart)

Higher Rates of Obesity Adversely Impacting Fertility

Table 10: Global Obesity Prevalence (2013): Percentage Share Breakdown of Obese Population by Leading Countries (includes corresponding Graph/Chart)

Cultural Shifts and Society Acceptance of Same-sex Marriage Boost ART


Medical Tourism on the Rise

Market Restraints

Variations in Regulations

Ethical, Religious and Legal Challenges

CONTRACEPTIVES

Table 12: Global Contraceptives Market by Segment (2013): Percentage Share Breakdown of Value Sales by Segment - Oral Contraceptives, Condoms, Implants/Injections, and Others (includes corresponding Graph/Chart)

Major Brands of Oral Birth Control Pills Worldwide by Type and Composition

Market Trends

Unmet Contraceptive Needs in Underdeveloped Countries

Major Hindrances for Widespread Usage of Condoms

Increasing Awareness of STDs Creates Additional Demand for Condoms

Drospirenone - Controversial Ingredient in Oral Contraceptive Pills

Contraceptive Manufacturers Focus on Extensive R&D

Innovative Condom Promotion Strategies Enhance Product Appeal

Female Condoms: Empowering the Woman of Today

Multifunctional Modern Contraceptives Make a Foray

UNFPA Boosts the Contraceptive Market in Emerging Economies

Emergency Contraception Receives Encouragement from Government

Public Health Organizations Spur Condoms Use

Favorable Demographic, Social and Economic Trends Strengthens Market Prospects

Table 13: World Population (2012): Population and Percentage Share Breakdown by Age Group - Below 15 Years, 15-64 Years, Above 65 Years (includes corresponding Graph/Chart)

Competition in the Condoms Market

Table 14: Leading Players in the Global Condoms Market (2013): Percentage Market Share by Revenue for Ansell, Church & Dwight, Okamoto, Reckitt Benckiser, and Others (includes corresponding Graph/Chart)

Table 15: Durex' Dominance Worldwide (2013): Market Shares in Select Regions (includes corresponding Graph/Chart)

3. INNOVATIONS IN THE HUMAN REPRODUCTIVE TECHNOLOGIES SPACE

Time-lapse Technology Allows Undisturbed Embryo Monitoring

Breakthrough Molecular Research to Make Male Contraception a Reality

Vasalgel - Revolutionary Male Contraceptive Polymer and Pill

Prediction of Chromosomal Abnormalities in Cell-1 Stage IVF Embryos

ICSI Results not Affected by Spermatozoa Source/Etiology

Autologous Mitochondrial Transfer for Enhanced IVF Success

PGD Assesses Risk of mtDNA Transfer to Child

Sunshine Found to Boost IVF Outcomes

Newer Innovations in the Contraceptive Market

Remote-Controlled Female Contraceptives

ART Bringing a Paradigm Shift in the Field of Cellular Biology

INVOCel Fosters Growth for the ART Industry

RISUG Technique Gains Recognition

4. TECHNOLOGY OVERVIEW
Reproduction: Preface
Male Reproductive System
Female Reproductive System
Dynamics of Reproductive Endocrinology
Human Reproductive Technologies
Male/Female Infertility: Causes & Treatment
Fertility Technologies and Procedures
Assisted Reproductive Technology (ART)
Table 16: Increasing ART Treatments: No. of ART Treatment in 1980, 1990, 2000, and 2010 (includes corresponding Graph/Chart)
In-Vitro Fertilization (IVF)
Ovarian Stimulation:
Egg Retrieval:
Fertilization:
Embryo Transfer:
Advantages of IVF
Embryo Screening for Inherited Diseases
Benefits for Single Women/Homosexual Couples
Use of Additional Embryos
Disadvantages of IVF
Multiple Pregnancies
Associated Side-Effects
Ectopic Pregnancy
Perinatal Outcomes for Singleton
Low Success Rate
Intrauterine Insemination (IUI)
Intracytoplasmic Sperm Injection (ICSI)
Other Fertility Technologies and Advancements
Cost-Effectiveness of ART
Medical Risks Associated with ART
Ethical Issues Associated with ART
Third-Party Assisted ART
Sperm Donation
Egg Donation
Surrogates or Gestational Carriers
CONTRACEPTION - OVERVIEW
User Involvement
Popular Devices and Methods of Contraception
Oral Contraceptive Pill
Intrauterine Devices
Barrier Contraceptives
Condoms - Types, Benefits, and Risks
Table 17: Condom Search Volume by Brand (2015): Percentage Share of Online Search Volumes for Leading Brands (includes corresponding Graph/Chart)
Transdermal Contraceptives
Transdermal Patch
Vaginal Ring
Subdermal Implants
Comparative Analysis of Contraceptive Implants
Emergency Contraception
Progestin Pills:
Ulipristal acetate:
Combined Pills:
Paragard® Copper-T IUD:
Comparison of Various Forms of Hormone-based and Non hormonal Emergency Contraception
Table 18: Effectiveness of Contraceptive Methods: Percentage of Unwanted Pregnancy Resulting from Various Contraceptive Means (includes corresponding Graph/Chart)
Historical Overview of Human Genetic and Reproductive Technologies

5. PRODUCT LAUNCHES/APPROVALS
Agile Announces USPTO Patent Allowances for New Contraceptive Regimens
Genea Biomedx Receives CE Certification for Gavi® and Geri®
Agile Announces Patent Issuance for Twirla® Patch
Teva Launches Generic Contraceptive Junel® Fe 24
Auxogyn's Eva™ System Receives FDA Clearance
Lupin Receives FDA Approval to Market Generic Lutera® (US)
EPO to Grant Patent to Auxogyn's Eva™ Test

6. RECENT INDUSTRY ACTIVITY
CooperSurgical Acquires Reprogenetics
Genea, Merck, and Illumina Form the Global Fertility Alliance
Genea Biomedx and Merck Sign Fertility Collaboration Agreement
Auxogyn and Fertility Authority Merge to Form Progyny
Collaboration Agreement to Expand Access to Pfizer's Sayana® Press
Reprogenetics Enters Into Partnership with Illumina
Cipla Medpro Enters into Collaboration with Teva Pharmaceuticals
Genea Starts European Manufacturing Operations
Ferring Pharmaceuticals Partners with Roche
OPMEDIC Group Becomes Privately Owned
Fertility Group Genea Creates IVF Technology Company Genea Biomedx
Auxogyn Enters Into Partnership with Valencia Infertility Institute
Agile Enters Into US$15 Million Financing Agreement with Oxford Finance

7. FOCUS ON SELECT GLOBAL PLAYERS
Actavis, Inc. (US)
Ansell Limited (Australia)
Agile Therapeutics, Inc. (US)
Bayer HealthCare (Germany)
Church & Dwight Co., Inc. (US)
Cipla Limited (India)
CellCura ASA (Norway)
Cook Medical (US)
CooperSurgical (US)
Ferring Pharmaceuticals (Switzerland)
Fuji Latex Co., Ltd. (Japan)
Genea Biomedx (Australia)
Merck KGAA (Germany)
Okamoto Industries (Japan)
Pfizer Inc. (US)
Progyny, Inc. (US)
Reckitt Benckiser Group Plc. (UK)
Sanofi (US)
Teva Pharmaceutical Industries Ltd. (Israel)
The Female Health Company (US)

8. GLOBAL MARKET PERSPECTIVE
Table 19: World Recent Past, Current & Future Analysis for Human Reproductive Technologies by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa, and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 20: World Historic Review for Human Reproductive Technologies by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa, and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 21: World 14-Year Perspective for Human Reproductive Technologies by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa, and Latin America Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)
Table 22: World Recent Past, Current & Future Analysis for Human Reproductive Technologies by Technology - Contraceptive and Infertility Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 23: World Historic Review for Human Reproductive Technologies by Technology - Contraceptive and Infertility Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 24: World 14-Year Perspective for Human Reproductive Technologies by Technology - Percentage Breakdown of Value Sales for Contraceptive and Infertility Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)
III. MARKET

1. THE UNITED STATES

A. Market Analysis
United States: The Leading Market for Human Reproductive Technologies
Pill Continues as One of the Most Popular Forms of Contraception

Table 25: The US Oral Contraceptives Market by Leading Brand (2013): Percentage Market Share Breakdown of Leading Oral Contraceptive Brands in Drugstores (includes corresponding Graph/Chart)

Condoms Market - Highly Concentrated

Table 26: The US Condoms Market by Leading Player (2014): Percentage Market Share Breakdown for Ansell America, Church and Dwight Co., Reckitt Benckiser and Others (includes corresponding Graph/Chart)

Table 27: The US Condoms Market by Leading Player (2014): Percentage Share Breakdown of Drugstore Sales for Ansell America, Church and Dwight Co., Reckitt Benckiser, and Others (includes corresponding Graph/Chart)

Domestic Condom Players Face Tough Competition from Foreign Brands

Increased Numbers of Female IVF Users

Table 28: The US Birth Rates by Maternal Age and Year: Rate of Birth in Women in the Age groups <20, 20-29, 30-34, and 35-39+ for the Years 2000, 2006, 2011 & 2013 (includes corresponding Graph/Chart)

Increasing Numbers of Female IVF Users

Rise in Successful Births from IVF, Multiple Births Decline Due to Modern Methods


List of State wise Policies on Requiring ERs to Dispense Emergency Contraception and Related Services

Women's Awareness and Usage of EC

Table 29: Emergency Contraceptive Awareness and Usage Among US Women by Age Group (2015): Percentage of Women who heard of EC & Percentage of Women who used EC (includes corresponding Graph/Chart)

Skyla IUD - Boon for Younger Women

Lack of Regulations - Blessing or Drawback?

Product Launches

Strategic Corporate Developments

Select Key Players

B. Market Analytics

Table 30: The US Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)

Table 31: The US Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)

2. CANADA

A. Market Analysis

Canada Lags Behind in Reproductive Technology

Compensation Banned for Surrogacy

Strategic Corporate Development

OPMEDIC Group Inc. - A Key Player

B. Market Analytics

Table 32: Canadian Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)

Table 33: Canadian Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)

3. JAPAN

A. Market Analysis

Oral Contraceptives Not Favored

Condoms Usage Continues to Soar

Major Condom Brands in Japan

Crown and Beyond Seven

Kimono Condoms

Select Key Players

B. Market Analytics

Table 34: Japanese Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)

Table 35: Japanese Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
4. EUROPE
A. Market Analysis
Table 36: European Market for Contraceptives (2013): Percentage Share Breakdown of Value Sales by Segment
Condoms, Implants/Injections, Oral Contraceptives and Others (includes corresponding Graph/Chart)
National Testing Labs Join Hands to Find Solutions for Improved Quality of Condom Testing
B. Market Analytics
Table 37: European Recent Past, Current & Future Analysis for Human Reproductive Technologies by Geographic Region
France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 38: European Historic Review for Human Reproductive Technologies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 39: European 14-Year Perspective for Human Reproductive Technologies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)
4a. FRANCE
Market Analysis
Table 40: French Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 41: French Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
4b. GERMANY
A. Market Analysis
Key Players
B. Market Analytics
Table 42: German Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 43: German Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
4c. ITALY
Market Analysis
Table 44: Italian Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 45: Italian Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
4d. THE UNITED KINGDOM
A. Market Analysis
Contraceptives - A Mature Market
Table 46: Condom Usage in the UK (2013): Breakdown of Usage Rate by Gender and Age (includes corresponding Graph/Chart)
Durex - The Dominant Brand
UK Government Approves Mitochondrial Replacement
Strategic Corporate Development
Reckitt Benckiser Group Plc. - A Key Player
B. Market Analytics
Table 47: The UK Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 48: The UK Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
4e. SPAIN
Market Analysis
Table 49: Spanish Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 50: Spanish Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
4f. RUSSIA
Market Analysis
Table 51: Russian Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 52: Russian Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)

4g. REST OF EUROPE

A. Market Analysis
Greece: Fertility Tourism to Mitigate Financial Crisis
Strategic Corporate Development
Key Players

B. Market Analytics

Table 53: Rest of European Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 54: Rest of European Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

A. Market Analysis
Government Incentives to Prevent “Low Fertility Trap”
Developing Asian Countries Offer Significant Growth Opportunities

Table 55: China and India Lead Global Population (July 2013): Table Depicting China and India's Huge Population Vis-a-vis Other Countries' Population (in Million) by Age Group (includes corresponding Graph/Chart)
Rising HIV/AIDS Prevalence

Table 56: Top Twelve Countries in Asia-Pacific with the Highest HIV Incidence (2012) (includes corresponding Graph/Chart)

Asia-Pacific Contraceptive Market
Table 57: Asia-Pacific Market for Contraceptives (2013): Percentage Share Breakdown of Value Sales by Region
China, India and Rest of Asia-Pacific (includes corresponding Graph/Chart)
Table 58: Asia-Pacific Market for Contraceptives (2013): Percentage Share Breakdown of Value Sales by Segment
Condoms, Implants/Injections, Oral Contraceptives, and Others (includes corresponding Graph/Chart)

B. Market Analytics

Table 59: Asia-Pacific Recent Past, Current & Future Analysis for Human Reproductive Technologies by Region
China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 60: Asia-Pacific Historic Review for Human Reproductive Technologies by Region - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 61: Asia-Pacific 14-Year Perspective for Human Reproductive Technologies by Region - Percentage Breakdown of Value Sales for China, India, and Rest of Asia-Pacific Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

5a. CHINA

A. Market Analysis
An Overview of the Chinese Market for Condoms
Condoms Market Exhibits Unprecedented Growth
Fight against HIV Augurs Well for Condoms Market
Chinese Condom Makers Eyeing Smaller Cities to Spruce up Sales

B. Market Analytics

Table 62: Chinese Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 63: Chinese Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)

5b. INDIA

A. Market Analysis
Preferred Destination for Reproductive Medical Tourism
Need for Proper Legislative Framework for Surrogacy and Egg Donation
Indian Condom Market Overview
Social Stigmas Continue to Hamper Growth
Male Condom Market Witnesses Growth
Price Cap on Condoms to Dent Premium Condom Market
India Witnesses Decline in Use of Government-Issued Condoms
Opportunities Abound for Female Condoms
NACO's Initiatives Spurs Female Condoms Use Challenges to Reckon With Usage of Female Condoms Remains a Challenge Indian Women Fairly Open to the Concept of Oral Contraceptives

Table 64: Indian OTC Contraceptive Pill Market by Brand (2012): Percentage Breakdown of Revenue for Malad, Choice, Saheli, Suvidha, Khushi & Others (includes corresponding Graph/Chart)
Cipla Limited - A Key Player

B. Market Analytics

Table 65: Indian Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 66: Indian Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)

Sc. REST OF ASIA-PACIFIC
A. Market Analysis
Australia Ban on Commercial Surrogacy Focus on Acquisitions and Consolidation Product Approval Strategic Corporate Developments Genea Biomedx (Australia) - A Key Player

B. Market Analytics
Table 67: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 68: Rest of Asia-Pacific Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)

6. THE MIDDLE EAST & AFRICA
A. Market Analysis
Africa Huge Opportunities in Store for Condom Makers South Africa Family Planning Programs: The Key Source for Condoms Strategic Corporate Development Teva Pharmaceutical Industries Ltd. (Israel) - A Key Player

B. Market Analytics
Table 69: The Middle East & Africa Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 70: The Middle East & Africa Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)

7. LATIN AMERICA
A. Market Analysis
Market for Female Condoms Still Nascent Table 71: Latin American Market for Contraceptives (2013): Percentage Share Breakdown of Value Sales by Segment Condoms, Implants/Injections, Oral Contraceptives and Others (includes corresponding Graph/Chart)

B. Market Analytics
Table 72: Latin American Recent Past, Current & Future Analysis for Human Reproductive Technologies by Region Brazil and Rest of Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 73: Latin American Historic Review for Human Reproductive Technologies by Region - Brazil and Rest of Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 74: Latin American 14-Year Perspective for Human Reproductive Technologies by Region - Percentage Breakdown of Value Sales for Brazil and Rest of Latin American Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)
7a. BRAZIL
A. Market Analysis Role of Condom Social Marketing (CSM) National Policy
National Regulation
B. Market Analytics
Table 75: Brazilian Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 76: Brazilian Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
7b. REST OF LATIN AMERICA
Market Analysis
Table 77: Rest of Latin American Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 78: Rest of Latin American Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 102 (including Divisions/Subsidiaries - 115)

The United States (28)
Canada (3)
Japan (3)
Europe (34)
  - France (1)
  - Germany (11)
  - The United Kingdom (6)
  - Italy (3)
  - Rest of Europe (13)
Asia-Pacific (Excluding Japan) (41)
Latin America (3)
Africa (2)
Middle East (1)

Ordering:
Order Online - [http://www.researchandmarkets.com/reports/362123/](http://www.researchandmarkets.com/reports/362123/)
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Human Reproductive Technologies - Global Strategic Business Report
Web Address: http://www.researchandmarkets.com/reports/362123/
Office Code: SC2G9P67

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>□</td>
<td>USD 4500</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users</td>
<td>□</td>
<td>USD 6300</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 10 Users</td>
<td>□</td>
<td>USD 8550</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 15 Users</td>
<td>□</td>
<td>USD 10800</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp